The Oncotype DX Breast Recurrence Score Test is Backed by Landmark Clinical Studies

Global Validation Studies for Patients with Early-Stage, ER+, HER2- Breast Cancer

Clinical validation studies are essential in the development of a genomic test. They help determine if the test is accurate by checking that the genes being analyzed actually relate to the presence or absence of disease.¹ The Oncotype DX Breast Recurrence Score test has been validated in many such studies, showing that Recurrence Score results do correlate with risk of recurrence and chemotherapy benefit.^2-12 The results from two recent, landmark studies can help patients make treatment decisions with more confidence:

TAILORx For Node-Negative Breast Cancer Patients

Is the largest ever breast cancer treatment trial identifying which node-negative patients can use hormonal therapy alone and can safely avoid the side-effects of chemotherapy.

What the study found:

• That the vast majority of early-stage breast cancer patients can safely forgo chemotherapy.²
• Women with low scores (Recurrence Score results 0-10) did not benefit from chemotherapy, and 99% of those patients did not have their breast cancer come back after 5 years when treated with hormonal therapy alone.¹¹
• Patients with Recurrence Score results less than or equal to 25 do not receive benefit from adding chemotherapy to their treatment plan.²

RxPONDER For Node-Positive Breast Cancer Patients

Is a treatment trial determining the benefit of chemotherapy in node-positive breast cancer patients with Recurrence Score results of 0 to 25.*

What the study found:

• The majority of node-positive patients can safely forgo chemotherapy.¹³
• Postmenopausal women with 1-3 positive nodes and a Recurrence Score result 0-25 can forgo chemotherapy.¹³

Learn more about what the Oncotype DX Test can Provide You

*Additional clinical data shows that women with node-positive breast cancer and Recurrence Score results greater than 25 benefit from adding chemotherapy to their treatment plan.¹⁴